Drug intelligence / Profile preview

methylcantharidimide

Development stage: Phase 4
Modality: Small Molecules
Administration: Oral

Overview

Methylcantharidimide is an orally bioavailable derivative of the terpenoid cantharidin—a natural toxin extracted from blister beetles. It is under investigation for its potential antineoplastic (anticancer) activity. The compound may exert a direct tumor cell killing effect in susceptible tumor cells when administered orally. The precise mechanism of action has not been fully elucidated but is believed to be related to its structural similarity to cantharidin and possible inhibition of protein phosphatases involved in cell cycle regulation and apoptosis. Methylcantharidimide is being studied in clinical trials for the treatment of large and unresectable hepatocellular carcinoma[1][3].

Other names: (3aR,4S,7R,7aS)-2,3a,7a-trimethyl-4,5,6,7-tetrahydro-4,7-epoxyisoindole-1,3-dione76970-78-062T9S2Y75E

Beyond the preview

Go deeper on methylcantharidimide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylcantharidimide.

Explore the full profile